Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care principal findings of the BP GUIDE study

Hypertension

Volumn 62, Issue 6, 2013, Pages 1138-1145

  Sharman, James E ^a   Marwick, Thomas H ^a   Gilroy, Deborah ^b   Otahal, Petr ^a   Abhayaratna, Walter P ^c   Stowasser, Michael ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Aorta; Clinical trial; Heart ventricles; Hemodynamics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; DRUG DOSE REDUCTION; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; THREE DIMENSIONAL ECHOCARDIOGRAPHY; AGED; AORTA; ARTERIAL PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MANAGEMENT; DRUG EFFECT; HEALTH CARE QUALITY; HEART VENTRICLE; HEMODYNAMICS; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; DRUG EFFECTS; PROCEDURES;

AORTA; CLINICAL TRIAL; HEART VENTRICLES; HEMODYNAMICS;

AGED; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BLOOD PRESSURE DETERMINATION; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84892367308     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02001     Document Type: Article

References (36)

1. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to Management of Hypertension. 2008:1-28.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
4. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
5. Cushman WC, Evans GW, Byington RP; ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362:1575-1585.
6. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142-2151.
7. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al; Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170-2179.
8. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-68.
9. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875-884.
10. Zhang Y, Zhang X, Liu L, Wang Y, Tang X, Zanchetti A; FEVER Study Group. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial? J Hypertens. 2012;30:2202-2212.
11. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe C V, et al; Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension. 2008;51:1476-1482.
12. Sharman J, Stowasser M, Fassett R, Marwick T, Franklin S. Central blood pressure measurement may improve risk stratification. J Hum Hypertens. 2008;22:838-844.
13. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol. 2008;105:1652-1660.
14. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39:735-738.
15. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865-1871.
16. Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, et al. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens. 2011;29:454-459.
17. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-1630.
18. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122-1128.
19. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 2009;15:272-289.
20. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
21. Sharman JE, Marwick TH, Abhayaratna WP, Stowasser M. Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing managEment of hypertension: the BP GUIDE study. Am Heart J. 2012;163:761-767.
22. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR; ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753-1760.
23. WHO Collaborating Centre for Drug Statistics Methodology. Daily defined dose: definition and general considerations. Oslo, Norway: Norwegian Institute of Public Health; 2012. http://www.whocc.no/ddd/definition-and-general- considera/. Accessed March 16, 2013.
24. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol. 1990;30:353-364.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
26. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol. 2004;44:878-886.
27. Jenkins C, Bricknell K, Chan J, Hanekom L, Marwick TH. Comparison of two- and three-dimensional echocardiography with sequential magnetic resonance imaging for evaluating left ventricular volume and ejection fraction over time in patients with healed myocardial infarction. Am J Cardiol. 2007;99:300-306.
28. Rogoza AN, Pavlova TS, Sergeeva MV. Validation of A&D UA-767 device for the self-measurement of blood pressure. Blood Press Monit. 2000;5:227-231.
29. Palatini P, Frigo G, Bertolo O, Roman E, Da Corta R, Winnicki M. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. Blood Press Monit. 1998;3:255-260.
30. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
31. Kelly RP, Gibbs HH, O'Rourke MF, Daley JE, Mang K, Morgan JJ, et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J. 1990;11:138-144.
32. Sharman JE, Laurent S. Central blood pressure in the management of hypertension: soon reaching the goal? J Hum Hypertens. 2013;27:405-411.
33. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1:113-119.
34. Howes F, Hansen E, Williams D, Nelson M. Barriers to diagnosing and managing hypertension-a qualitative study in Australian general practice. Aust Fam Physician. 2010;39:511-516.
35. Cox ML, Bennett JB 3rd, Dudley GA. Exercise training-induced alterations of cardiac morphology. J Appl Physiol. 1986;61:926-931.
36. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.